Blood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers

Adam Kiljańczyk,Milena Matuszczak,Wojciech Marciniak,Róża Derkacz,Klaudia Stempa,Piotr Baszuk,Marta Bryśkiewicz,Krzysztof Lubiński,Cezary Cybulski,Tadeusz Dębniak,Jacek Gronwald,Tomasz Huzarski,Marcin R Lener,Anna Jakubowska,Marek Szwiec,Małgorzata Stawicka-Niełacna,Dariusz Godlewski,Artur Prusaczyk,Andrzej Jasiewicz,Tomasz Kluz,Joanna Tomiczek-Szwiec,Ewa Kilar-Kobierzycka,Monika Siołek,Rafał Wiśniowski,Renata Posmyk,Joanna Jarkiewicz-Tretyn,Ping Sun,Rodney J Scott,Steven A Narod,Jan Lubiński

DOI: https://doi.org/10.3390/nu16091370

IF: 5.9

2024-04-30

Nutrients

Abstract:BRCA1 mutations substantially elevate the risks of breast and ovarian cancer. Various modifiers, including environmental factors, can influence cancer risk. Lead, a known carcinogen, has been associated with various cancers, but its impact on BRCA1 carriers remains unexplored. A cohort of 989 BRCA1 mutation carriers underwent genetic testing at the Pomeranian Medical University, Poland. Blood lead levels were measured using inductively coupled plasma mass spectrometry. Each subject was assigned to a category based on their tertile of blood lead. Cox regression analysis was used to assess cancer risk associations. Elevated blood lead levels (>13.6 μg/L) were associated with an increased risk of ovarian cancer (univariable: HR = 3.33; 95% CI: 1.23-9.00; p = 0.02; multivariable: HR = 2.10; 95% CI: 0.73-6.01; p = 0.17). No significant correlation was found with breast cancer risk. High blood lead levels are associated with increased risk of ovarian cancer in BRCA1 carriers, suggesting priority for preventive salpingo-oophorectomy. Potential risk reduction strategies include detoxification. Validation in diverse populations and exploration of detoxification methods for lowering lead levels are required.